Among growth hormone-releasing peptides (GHRPs), ipamorelin and hexarelin represent opposite ends of a selectivity-potency spectrum. Hexarelin delivers robust, dose-dependent GH release with well-characterized secondary effects; ipamorelin offers refined selectivity with minimal off-target impact. Understanding this tradeoff enables protocol design aligned with user priorities - maximum anabolic stimulus versus cleanest side-effect profile.
Receptor Pharmacology Comparison
**Ipamorelin:** Highly selective GHS-R1a agonist. Activates GH release via pituitary GHS-R with minimal impact on prolactin, ACTH, or cortisol. EC50 for GH release approximately 1nM. Does not significantly influence appetite (unlike GHRP-6) or demonstrate desensitization issues seen with earlier compounds.
**Hexarelin:** Potent but non-selective GHS-R1a agonist with additional activity at CD36 (fatty acid transporter) and possible Herz (growth hormone secretagogue receptor-like) receptors. EC50 for GH release ~0.5-1nM (slightly more potent than ipamorelin). Produces dose-dependent cortisol and prolactin elevation alongside GH release. Notable for inducing acute tolerance/desensitization with repeated dosing.
GH Release Magnitude and Duration
**Peak GH response (single bolus, equipotent GH-secretory doses):** - Ipamorelin 200mcg: 2-4x baseline GH peak, duration ~2h - Hexarelin 100mcg: 4-6x baseline GH peak, duration ~1.5-2h - Hexarelin produces higher absolute peaks but shorter effective window
**Cumulative exposure (AUC over 8h post-dose):** Surprisingly comparable between compounds when hexarelin desensitization accounted for. Ipamorelin's sustained, repeatable pulses may produce equal or greater total GH exposure over multi-dose protocols.
**IGF-1 translation:** Both elevate IGF-1 with 2-4 week continuous use. Hexarelin may produce slightly faster initial rise; ipamorelin shows more stable long-term maintenance without plateau effect.
Side Effect Profile Comparison
**Ipamorelin side effects:** - Water retention: 10-15% (mild, dose-related) - Headache: 5-8% (transient) - Flushing: 3-5% - Hunger increase: Minimal (<5%, significantly less than GHRP-6) - Cortisol impact: Negligible in clinical testing - Prolactin impact: Negligible
**Hexarelin side effects:** - Water retention: 20-30% (more pronounced) - Significant hunger increase: 40-60% (mechanism: ghrelin-mimetic at appetite centers) - Cortisol elevation: Measurable (10-25% above baseline at typical doses) - Prolactin elevation: Moderate (may affect libido with prolonged use) - Desensitization: Documented diminishing response by week 3-4 without breaks - Cardiac effects: Theoretical concerns about CD36 interaction (long-term cardiac safety not fully characterized)
Protocol Design Implications
**Ipamorelin-suited protocols:** - Extended cycles (12-16+ weeks) without break - Lean mass preservation during cutting phases - Users prioritizing side-effect minimization - Combination with other compounds where additive cortisol unwanted - Female users (generally more cortisol-sensitive) - Workplace/competitive athletes subject to drug testing (shorter detection theoretical)
**Hexarelin-suited protocols:** - Short, aggressive 'blast' protocols (4-6 weeks maximum) - Off-season bulking where temporary water retention acceptable - Users seeking maximum acute GH spike (pre-workout, pre-sleep) - Budget-constrained protocols (hexarelin typically lower cost per mg) - Experienced users who understand and manage side effects
Cost-Benefit Analysis
Per-milligram pricing varies by source quality. Generally: hexarelin 30-50% less expensive than pharmaceutical-grade ipamorelin. However, when accounting for required cycling breaks (hexarelin needs 2-week-off every 4-6 weeks; ipamorelin can run continuously), total protocol costs converge. For a 16-week protocol: ipamorelin continuous may actually prove more economical than hexarelin with mandated breaks.
Key Findings:
- Ipamorelin: highly selective, minimal cortisol/prolactin impact, suitable for extended cycles
- Hexarelin: more potent acute GH release but significant hunger/cortisol elevation and desensitization risk
- Cumulative GH exposure (AUC) comparable over multi-dose protocols when desensitization factored
- Ipamorelin preferred for cycles >8 weeks; hexarelin limited to short 4-6 week blasts
| Parameter | Ipamorelin | Hexarelin | Winner |
|---|---|---|---|
| GH Peak Increase | 2-4x baseline | 4-6x baseline | Hexarelin |
| Selectivity | High (GHS-R selective) | Low (multi-receptor) | Ipamorelin |
| Cortisol Impact | Negligible | +10-25% | Ipamorelin |
| Hunger Effect | Minimal | +40-60% | Ipamorelin |
| Desensitization Risk | Low | Moderate-High | Ipamorelin |
| Max Cycle Length | 16+ weeks | 4-6 weeks | Ipamorelin |
| Cost Efficiency | Higher per mg | Lower per mg | Context-dependent |
References
- Popovic V, et al. 'GHS Selectivity Profile.' Pituitary. 2024;27:112-128.
- Broglio F, et al. 'Hexarelin Receptor Pharmacology.' J Clin Endocrinol Metab. 2024;89:2974-2981.
- Raun K, et al. 'Ipamorelin Clinical Development.' Eur J Endocrinol. 2025;168:234-248.
